bims-evecad Biomed News
on Extracellular vesicles and cardiovascular disease
Issue of 2026–08–16
fourteen papers selected by
Cliff Dominy



  1. Int J Mol Sci. 2026 Jul 29. pii: 6786. [Epub ahead of print]27(15):
      The rising prevalence of cardiovascular diseases (CVDs) worldwide imposes a substantial economic burden on healthcare systems. Despite major advances in evidence-based therapies and modern healthcare, the demand for novel, time- and cost-effective treatment options continues to grow. Extracellular vesicles (EVs), including apoptotic bodies, microvesicles, and exosomes, are released by numerous cell types and mediate intercellular communication in both physiological and pathological contexts. To date, researchers have amassed compelling evidence for the functional roles of EVs in the development and progression of myocardial disease, supporting their exploration for clinical applications. In this review, we examine the multifunctional roles of EVs from diverse cellular origins in prominent CVD manifestations, highlighting publications of the last eight years and their key findings. They confirm that EVs carry disease-specific molecular cargo, particularly microRNAs, long non-coding RNAs, proteins, and other bioactive molecules, contributing to inflammation, oxidative stress, fibrosis, endothelial dysfunction, and cardiac remodeling, while also serving as promising diagnostic and prognostic biomarkers. Furthermore, emerging preclinical evidence demonstrates the therapeutic potential of engineered or tissue-derived EVs for promoting cardiac repair and limiting adverse cardiac remodeling.
    Keywords:  biomarker discovery; cardiovascular diseases; cell communication; extracellular vesicles
    DOI:  https://doi.org/10.3390/ijms27156786
  2. Circ Res. 2026 Aug 14. 139(5): e327198
      Cardiovascular diseases remain the leading global cause of mortality, highlighting the need for improved early detection and targeted interventions. Extracellular vesicles (EVs) are nano-sized, bilipid-layered particles released by all cell types that carry RNAs, proteins, lipids, and metabolites reflective of their parent cells. They mediate intercellular communication by transferring cargo that alters recipient cell transcriptomic and proteomic states, and this property may be leveraged for therapeutic delivery. This review provides a comprehensive, cardiovascular disease-focused synthesis of EV biology with emphasis on what is clinically actionable and mechanistically novel. The review describes EV biogenesis and their multiomic cargo composition, followed by tissue-resolved and cell type-resolved EV signaling across cell types relevant to cardiovascular disease. A dedicated section addresses EV-mediated interorgan crosstalk across the heart-kidney, heart-liver, brain-heart, and adipose-heart axes as a systems-level framework for cardiometabolic disease. We next turn to translational applications, describing EV cargo composition under pathological conditions with implications for disease-related signaling and the potential for biomarker development. For liquid biopsy applications, the review introduces a 3-tier evidence framework classifying circulating EV biomarkers by clinical validation status, supported by a practical preanalytical checklist for cardiovascular plasma studies. Engineered, stem cell-derived, and RNA-loaded EV therapeutic modalities are evaluated, and active clinical trials are catalogued along with key challenges in cargo loading, biodistribution, immunogenicity, and regulatory standardization. We conclude with a structured future directions and perspectives section identifying the most tractable open questions required to advance EVs from discovery to cardiovascular clinical practice.
    Keywords:  biomarkers; cardiovascular diseases; cell communication; drug delivery systems; extracellular vesicles; liquid biopsy; microRNAs
    DOI:  https://doi.org/10.1161/CIRCRESAHA.126.327198
  3. Cells. 2026 Aug 05. pii: 1416. [Epub ahead of print]15(15):
      Cardiovascular diseases remain a major global health burden. Plant-derived extracellular vesicles (PDEVs) are increasingly being investigated as potential therapeutic and drug-delivery platforms for cardiovascular disease. PDEVs are natural nanovesicles carrying bioactive lipids, proteins, nucleic acids, and phytochemicals. Preclinical studies suggest that selected PDEV preparations may exert protective effects in cardiovascular disease-related models by modulating inflammation, oxidative stress, lipid metabolism, and endothelial repair. In experimental models, selected PDEVs have shown preliminary improvements in cargo stability, lesion accumulation, controlled release, and local retention through drug loading, surface ligand modification, responsive design, and integration with biomaterials. This review summarises the biogenesis, isolation, characterisation, and cardiovascular actions of PDEVs, with emphasis on their engineering and targeted delivery applications in atherosclerosis, myocardial infarction, ischaemia-reperfusion injury, vascular calcification, restenosis, and cardiotoxicity. Current challenges, including insufficient standardization, uncertain regulatory classification, unclear mechanisms, and limited pharmacokinetic and long-term safety data, are also discussed. Addressing these issues is essential for reliably evaluating the clinical translation potential of PDEVs.
    Keywords:  cardiovascular diseases; clinical translation; mechanisms; plant-derived extracellular vesicles; targeted drug delivery
    DOI:  https://doi.org/10.3390/cells15151416
  4. Front Pharmacol. 2026 ;17 1848964
      Heart failure (HF), the terminal stage of most cardiovascular diseases, remains a major global health burden with limited therapeutic options that do not fully achieve myocardial repair or functional recovery. Extracellular vesicles (EVs), nanoscale membrane-bound particles released by cells, have been increasingly recognized as important mediators in the pathophysiology of HF and as potential therapeutic targets. As intercellular messengers carrying bioactive molecules, including proteins, lipids, and non-coding RNAs, EVs regulate gene expression and functional states in recipient cells. This review summarizes current evidence on the roles of EVs in key pathological processes of HF, including inflammation, mitochondrial dysfunction, myocardial hypertrophy, fibrosis, apoptosis, and angiogenesis. We also discuss their potential as circulating biomarkers for the diagnosis and prognosis of HF. In addition, we describe emerging therapeutic strategies, including stem cell-derived EVs and engineered EVs as delivery platforms for therapeutic molecules. Furthermore, we discuss the pharmacological implications of EVs in current heart failure treatment paradigms, highlighting their potential role in bridging mechanistic insights with clinical therapeutic strategies. Collectively, these findings highlight the relevance of EVs in HF research and suggest directions for future investigation.
    Keywords:  biomarkers; extracellular vesicle; heart failure; non-coding RNAs; pathogenesis; therapeutic applications
    DOI:  https://doi.org/10.3389/fphar.2026.1848964
  5. Front Cardiovasc Med. 2026 ;13 1831078
      Cardiovascular disease remains the leading cause of morbidity and mortality worldwide, with atherosclerosis representing its principal pathological basis. High-density lipoproteins (HDL) and extracellular vesicles (EVs) are abundant circulating particles implicated in lipid metabolism, vascular inflammation, intercellular communication, and thrombotic processes relevant to atherosclerosis. Although HDLs and EVs differ in origin, structure, biogenesis, and canonical function, they share overlapping physicochemical and molecular features. Their density ranges substantially overlap, and small EV populations may approach the upper size range of HDL particles, making their separation from plasma technically challenging. As a result, common isolation workflows may generate HDL-enriched or EV-enriched fractions rather than fully particle-specific preparations, complicating the interpretation of proteomic, lipidomic, nucleic acid, and functional studies. This review compares the structural and biophysical characteristics, biogenesis pathways, molecular cargo, and atherosclerosis-related functions of HDLs and EVs. We highlight how both particle classes contribute to endothelial activation, inflammation, cholesterol handling, foam cell formation, plaque progression, and thrombosis, while also emphasizing their distinct biological roles. Finally, we discuss whether HDL-EV overlap should be interpreted solely as methodological co-isolation or may also reflect biologically relevant interactions within circulating nanoparticle networks in atherosclerosis.
    Keywords:  atherosclerosis; cardiovascular disease; circulating nanoparticles; extracellular vesicle cargo; extracellular vesicle isolation; extracellular vesicles; high-density lipoproteins; lipoprotein-extracellular vesicle interactions
    DOI:  https://doi.org/10.3389/fcvm.2026.1831078
  6. Biology (Basel). 2026 Jul 31. pii: 1260. [Epub ahead of print]15(15):
      Cardiovascular diseases (CVDs) remain the foremost cause of death globally, responsible for 19.2 million deaths and 437 million disability-adjusted life years in 2023, with prevalent cases having more than doubled since 1990. No approved therapy restores myocardium lost to infarction. The adult heart replaces cardiomyocytes at approximately 1% per year in young adults, declining to about 0.45% per year with ageing, far below what is needed to recover the more than one billion cells destroyed by a large myocardial infarction. Cell-based regenerative strategies have been investigated for more than two decades, encompassing bone marrow mononuclear cells (BM-MNCs), mesenchymal stromal cells (MSCs), cardiac progenitor cells, cardiosphere-derived cells (CDCs), skeletal myoblasts, and induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). Safety has been consistent. Efficacy has been modest and variable: the CADUCEUS trial demonstrated scar mass reduction with CDCs without proportionate ejection fraction improvement; the Phase 1/2 POSEIDON trial confirmed MSC safety in 30 patients; and the Phase 3 DREAM-HF trial, enrolling 537 patients, failed its primary endpoint (HR 1.2, p = 0.406). Mechanistic work has established that transplanted cells engraft poorly and exert their benefit principally through paracrine signalling mediated by secreted extracellular vesicles and exosomes carrying microRNAs, trophic factors, and immunomodulatory proteins. For iPSC-CMs, electrophysiological immaturity and arrhythmogenic risk in primate models remain unresolved barriers. Emerging strategies include CRISPR-engineered hypoimmune iPSC lines, bioengineered cardiac patches, injectable hydrogel scaffolds, and engineered exosome platforms. This review provides a comprehensive synthesis of preclinical and clinical evidence, examines translational barriers, and identifies the scientific and regulatory priorities required before these therapies can enter routine clinical practice.
    Keywords:  cardiac progenitor cells; cardiovascular disease; cell-based therapy; exosomes; extracellular vesicles; induced pluripotent stem cells; mesenchymal stromal cells; myocardial infarction; paracrine signalling; tissue engineering
    DOI:  https://doi.org/10.3390/biology15151260
  7. Nutrients. 2026 Aug 05. pii: 2564. [Epub ahead of print]18(15):
       BACKGROUND: Non-invasive therapies for heart failure represent one of the current major focuses in clinical research. Plant-derived extracellular vesicles (PEVs) have recently emerged as a promising therapeutic modality.
    OBJECTIVES: In this study, we investigated the therapeutic potential of PEVs in heart failure with preserved ejection fraction (HFpEF), focusing on extracellular vesicles derived from Lycium barbarum (Gq-EVs).
    METHODS: We first obtained Gq-EVs with high biological activity and high concentration from Lycium barbarum juice and characterized them by using transmission electron microscopy, nanoparticle tracking analysis, and metabolite composition analysis.
    RESULTS: Our in vivo findings indicate that nebulized inhalation of Gq-EVs for 7, 14, and 21 days improved abnormal cardiac diastolic function, reduced excessive myocardial hypertrophy, and attenuated inflammatory cell infiltration and collagen deposition in HFpEF mice. Further in vivo and in vitro experiments showed that Gq-EVs can reach injured cardiac tissue, improve mitochondrial function, and are associated with reduced cardiomyocyte apoptosis and amelioration of myocardial hypertrophy, potentially involving TP53-related apoptotic signaling.
    CONCLUSIONS: Overall, nebulized delivery of Gq-EVs may be a relatively non-invasive, well-tolerated, and cost-effective therapeutic strategy for HFpEF, highlighting the potential of PEV-based nanotherapies and offering a sustainable approach for the medical utilization of Lycium barbarum resources.
    Keywords:  Lycium barbarum-derived extracellular vesicles; TP53; apoptosis; heart failure with preserved ejection fraction; mitochondrial function; myocardial hypertrophy
    DOI:  https://doi.org/10.3390/nu18152564
  8. J Control Release. 2026 Aug 11. pii: S0168-3659(26)00659-0. [Epub ahead of print]398 115255
      Myocardial infarction (MI) remains a major challenge in clinical practice, as the irreversible loss of cardiomyocytes and the limited repair capacity of the adult heart constrain cardiac repair. Traditional cell therapy once held great promise, but its clinical application has been constrained by issues such as low cell survival, immune rejection and procedural complexity. Against this background, extracellular vesicles (EVs) have attracted attention as a paracrine delivery strategy. By delivering bioactive cargo, including proteins, nucleic acids and lipids, EVs mediate intercellular communication and thereby support cardiac repair. This review focuses on the clinical potential of EVs, comparing the advantages, limitations and safety risks of EVs from different cellular origins, and places particular emphasis on engineered delivery strategies aimed at improving targeting, retention and therapeutic efficacy. In parallel, we examine the core barriers to clinical translation, including large scale manufacturing challenges, batch to batch consistency, storage stability, and regulatory and ethical issues; it is these barriers, rather than insufficient efficacy, that constitute the key bottleneck to the clinical application of EVs. Compared with existing reviews, this review, by emphasizing a clinical translation perspective, systematically analyzes the key issues facing EV-based therapeutic strategies in their progression from experimental research to clinical application, providing a practical theoretical framework for EV-based myocardial repair therapies and clarifying the prospects for EVs in the treatment of MI.
    Keywords:  Clinical translation; Engineering strategies; Extracellular vesicles; Myocardial infarction
    DOI:  https://doi.org/10.1016/j.jconrel.2026.115255
  9. Int J Mol Sci. 2026 Aug 03. pii: 6966. [Epub ahead of print]27(15):
      Non-communicable diseases (NCDs), including type 2 diabetes mellitus (DM), hypertension (HTA), obesity (OB), and cardiovascular disease (CVD), represent a major global health burden and disproportionately affect socially vulnerable populations. Small extracellular vesicles (EVs) are stable carriers of proteins and regulatory RNAs that may reflect endothelial dysfunction and cardiometabolic stress. This study explored plasma-derived EV-associated biomarkers in adults from La Guajira, Colombia, with emphasis on miR-126-3p, miR-21-5p, miR-92a-3p, and SNAIL. Anthropometric, clinical, and biochemical data were obtained from a cross-sectional cohort. Representative plasma samples were selected for EVs isolation by size-exclusion chromatography. Vesicles were characterized by nanoparticle tracking analysis, scanning transmission electron microscopy, protein quantification, Western blotting, and bead-based flow cytometry. Candidate miRNAs were identified by small RNA sequencing and validated by stem-loop RT-qPCR. Bioinformatic enrichment analyses were performed using miRNet 2.0 and KEGG pathway analysis. The epidemiological cohort showed a high cardiometabolic burden, with waist-to-height ratio (WHtR) and triglyceride-glucose (TyG) index emerging as key markers of central adiposity and metabolic dysfunction. Plasma-derived EVs displayed the expected nanoscale morphology and expressed canonical vesicle markers. Protein cargo analyses revealed EMT- and remodeling-associated proteins, including SNAIL and GAL-3. EV-associated miR-126-3p, miR-21-5p, and miR-92a-3p were enriched predominantly in hypertensive and hypertensive-diabetic groups. In an exploratory sub-cohort, CD31-positive EVs showed a trend toward increased expression in individuals with previous myocardial infarction or stroke (p = 0.057). KEGG enrichment analysis linked the identified miRNA signature to pathways involved in endothelial dysfunction, inflammation, vascular remodeling, apoptosis, and extracellular matrix organization. Plasma-derived EVs from individuals with cardiometabolic disorders carry molecular signatures consistent with endothelial stress and vascular remodeling. These findings identify miR-126-3p, miR-21-5p, miR-92a-3p, SNAIL, and CD31-positive EVs as exploratory candidate biomarkers that require validation in larger prospective cohorts.
    Keywords:  biomarkers; cardiometabolic diseases; endothelial dysfunction; extracellular vesicles; miRNAs; snail; type 2 diabetes; vulnerable populations
    DOI:  https://doi.org/10.3390/ijms27156966
  10. Curr Neuropharmacol. 2026 Jul 30.
      Ischemic stroke damages complex, interconnected communication networks in addition to causing the destructive collapse of cells. All elements of the neurovascular unit (NVU), including the often disregarded glycocalyx and invading peripheral immune cells, interact dynamically and frequently contradict one another in their pathophysiological processes, which extend beyond neurons. This paper reviews developments in intercellular communication pathways that regulate brain injury and repair after cerebral ischemia. The intricate signaling networks among neurons, astrocytes, microglia, oligodendrocytes, endothelial cells, pericytes, and lymphocytes were comprehensively analyzed. This review goes beyond conventional viewpoints to highlight major findings, ongoing debates, and critical research gaps associated with each interaction. This study investigated the dual nature of glial responses by analyzing diverse activation states of glial cells, the mechanisms underlying blood-brain barrier (BBB) disruption, including glycocalyx degradation, and the complex immunoregulatory roles of lymphocyte subsets, such as regulatory T cells (Tregs), regulatory B cells (Bregs), and γδ T cells. In addition to classical soluble factor signaling, emerging communication mechanisms, including extracellular vesicles (EVs), tunneling nanotubes (TNTs), and migrasomes, were investigated, and these mechanisms may be involved in ischemic pathophysiology. Contradictory data and mechanistic evidence were assessed for every communication pathway; knowledge gaps were identified, and specific experiments were proposed to resolve these uncertainties. Finally, these observations were integrated into a discussion of advanced therapeutic approaches based on network modulation. This review offers a potential framework for discovering new system-based treatment targets targeted at rewiring harmful crosstalk and fostering strong neurological recovery by characterizing ischemic stroke as a progressive failure of intercellular communication.
    Keywords:  Cerebral ischemia; extracellular vesi-cles; glycocalyx; immune cells; intercellular communication; migrasome; neuroinflammation
    DOI:  https://doi.org/10.2174/011570159X460709260721113119
  11. Cells. 2026 Jul 24. pii: 1322. [Epub ahead of print]15(15):
      Ischemic stroke remains a leading cause of death and long-term disability worldwide. Although acute reperfusion therapies have improved outcomes in selected patients, effective strategies that directly promote neurovascular repair during the subacute and chronic phases remain limited. Vascular network remodeling in the peri-infarct region is increasingly recognized as a key process supporting tissue repair, blood-brain barrier restoration, and functional recovery after stroke. Microglia, as resident immune cells of the central nervous system, undergo dynamic morphological, metabolic, and functional changes after ischemic injury and participate in inflammation, phagocytic clearance, blood-brain barrier regulation, and tissue repair. Among repair-associated microglial states, microglia with M2d-like features have attracted increasing attention because of their potential association with immunoregulation and pro-vascular repair. However, whether repair-associated microglia with M2d-like features represent a distinct and stable microglial subtype after stroke remains unresolved. In this review, we summarize current evidence linking repair-associated microglial responses to vascular network remodeling after ischemic stroke, with particular emphasis on the conceptual value of the M2d-like state. We discuss putative mechanisms involving paracrine signaling, perivascular localization, metabolic reprogramming, and extracellular vesicle-mediated communication. We also evaluate therapeutic implications, including traditional Chinese medicine, extracellular vesicle-based strategies, and nanodelivery systems. However, current therapeutic evidence does not establish that these interventions specifically induce M2d-like microglial states. We highlight the need for rigorous validation of cellular identity, spatial localization, and functional vascular outcomes. Overall, the M2d-like framework provides a candidate perspective for understanding immune-vascular coupling after stroke, but further studies integrating single-cell omics, spatial mapping, lineage tracing, and functional vascular assessment are required to define the identity and functional contribution of repair-associated microglia with M2d-like features. Method: This article is a narrative review. The relevant literature was searched in PubMed from database inception to June 2026 using combinations of the terms "ischemic stroke," "microglia," "macrophage," "vascular remodeling," "angiogenesis," "M2d," "extracellular vesicles," "traditional Chinese medicine," and "nanomedicine." Priority was given to original studies directly examining microglial or myeloid responses and vascular repair after ischemic stroke. Relevant review articles were included to provide conceptual background. Because direct evidence for M2d-like microglial responses after stroke remains limited, selected studies involving peripheral macrophages, tumor-associated macrophages, traditional Chinese medicine, extracellular vesicles, and nanomedicine were included as indirect or hypothesis-generating evidence. Evidence was interpreted according to the disease model, cellular source, and vascular outcomes examined, with stroke-specific microglial studies regarded as more directly relevant than evidence extrapolated from non-stroke or non-microglial models.
    Keywords:  M2d-like features; angiogenesis; blood–brain barrier; extracellular vesicles; ischemic stroke; neurovascular unit; repair-associated microglia; traditional Chinese medicine; vascular network remodeling
    DOI:  https://doi.org/10.3390/cells15151322
  12. FASEB J. 2026 Aug 31. 40(16): e72182
      It is known that lipopolysaccharides (LPS) could lead to kidney injury and may play a role in intracavitary lithotripsy surgeries such as percutaneous nephrolithotomy (PCNL). Remote ischemic preconditioning (RIPC) has been demonstrated to have protective effects against kidney injury caused by various factors; however, its role in LPS-induced kidney injury remains unclear and its mechanisms require further exploration. Previous studies have shown that extracellular vesicles (EVs) induced by hypoxia mediated the renal protective effects of RIPC. In this study, we established a kidney injury model in rats by ligating the left ureter and injecting LPS into the renal pelvis, along with simultaneous removal of the right kidney (U-L model); EVs were isolated from the plasma of rats subjected to RIPC or sham treatment and administered to U-L model rats. Separately, EVs obtained from healthy human volunteers were applied to LPS-treated human renal tubular epithelial cells (HK-2). Results indicated that RIPC-EVs(R) reduced kidney injury caused by U-L by inhibiting apoptosis, inflammation, and oxidative stress. In vitro, RIPC-EVs(H) alleviate LPS-induced HK-2 cell injury by attenuating apoptosis and inflammation. Moreover, we identified 37 significantly upregulated differential proteins in the EVs sourced from human plasma after RIPC through 4D label-free proteomics, including Tenascin-C (TNC). Mechanistic studies revealed that RIPC-EVs(H) activated β-catenin, inhibited the p53 and NF-κB signaling pathways, and alleviated kidney injury. Clinical trial data showed that RIPC reduced the expression of kidney injury biomarkers in patients undergoing PCNL for kidney stones. Overall, the present study suggested that RIPC could mitigate kidney injury induced by LPS, possibly through the protective role of Tenascin-C carried by EVs.
    Keywords:  RIPC; extracellular vesicles; kidney injury; protein mass; retrograde intrarenal surgery
    DOI:  https://doi.org/10.1096/fj.202600108RR
  13. Biochem Biophys Res Commun. 2026 Aug 06. pii: S0006-291X(26)01172-1. [Epub ahead of print]833 154408
      Atherosclerosis is a chronic inflammatory disorder of the arterial wall and remains the leading pathological basis for myocardial infarction and ischemic stroke worldwide. Despite advances in imaging and risk-prediction models, early detection of subclinical atherosclerosis and identification of plaque vulnerability remain challenging. Conventional biomarkers such as low-density lipoprotein cholesterol, triglycerides, and high-density lipoprotein cholesterol provide valuable risk estimates but lack sufficient sensitivity and specificity for early disease detection and plaque vulnerability assessment, prompting growing interest in non-traditional and emerging biomarkers, as well as instrumental surrogate markers such as pulse wave velocity, which better reflect the complex molecular and mechanical processes underlying atherogenesis. This review provides a comprehensive, mechanism-based overview of traditional and emerging biomarkers associated with atherosclerosis, including inflammatory mediators, coagulation factors, cardiac-specific proteins, adhesion molecules, microRNAs, extracellular vesicles, and novel cytokines, alongside a comparative appraisal of the major non-invasive, functional, invasive, and nuclear imaging modalities used for plaque detection and characterization. Particular emphasis is placed on recently identified biomarkers such as midkine, pentraxin-3, soluble ST2, growth differentiation factor-15, and myeloperoxidase, including their tissue-specific origins and interpretive limitations, which show promise in improving early diagnosis, risk stratification, and prognostic evaluation. Biomarkers are further mapped to the key pathological stages of atherogenesis, endothelial dysfunction, lipid retention and oxidation, vascular inflammation, immune cell activation, plaque destabilization, and thrombotic activation, offering a physiologically intuitive framework for interpreting multi-marker panels. Understanding the biological relevance and clinical utility of these biomarkers may facilitate more precise cardiovascular risk assessment and support the development of targeted preventive and therapeutic strategies.
    Keywords:  Atherosclerosis; Cardiovascular biomarkers; Emerging biomarkers; Inflammation; Risk stratification
    DOI:  https://doi.org/10.1016/j.bbrc.2026.154408
  14. Int J Mol Sci. 2026 Jul 25. pii: 6639. [Epub ahead of print]27(15):
      Elevated plasma lipoprotein(a) [Lp(a)] levels represent a predominantly genetically determined risk factor for atherosclerotic cardiovascular disease and calcific aortic valve disease (CAVD). Mechanistically, Lp(a) transports oxidized phospholipids, lysophosphatidylcholine, and autotaxin, components capable of promoting inflammation, oxidative stress, and valvular fibrocalcific remodeling. This review synthesizes the molecular, cellular, and clinical evidence linking Lp(a) to CAVD progression. Retention of Lp(a) and other apolipoprotein B-containing lipoproteins in the valvular matrix promotes endothelial activation, recruitment of cells of the monocytic lineage, and the release of proinflammatory mediators. Oxidized phospholipids and the autotaxin-lysophosphatidic acid axis activate redox-dependent pathways and promote the transition of valvular interstitial cells toward myofibroblastic and/or osteogenic phenotypes. These processes converge in alterations in cholesterol metabolism, the release of procalcifying extracellular vesicles, and hydroxyapatite nucleation. Genetic and imaging evidence supports an association between elevated Lp(a), microcalcifying activity, and accelerated hemodynamic progression. Although anti-Lp(a) therapies substantially reduce plasma Lp(a) concentrations, their effect on valvular outcomes has not yet been demonstrated.
    Keywords:  aortic stenosis; autotaxin; calcified aortic valve disease; cardiovascular calcification; lipoprotein(a); oxidative stress; oxidized phospholipids; valvular inflammation
    DOI:  https://doi.org/10.3390/ijms27156639